Kaposi sarcoma (KS) is an angioproliferative neoplasm associated with human herpesvirus-8. Gastrointestinal KS has been well documented in immunosuppressed solid organ transplant patients, with only 26 iatrogenic cases published in patients with inflammatory bowel disease. We report a 24-year-old patient with ulcerative colitis, maintained on cyclosporine for 2 years, who presented with watery, nonbloody diarrhea and weight loss. Colonoscopy revealed human herpesvirus-8-positive hemorrhagic nodules throughout the colon and terminal ileum, with diffuse lymphadenopathy on computed tomography consistent with KS. As gastrointestinal KS may present with symptoms that mimic inflammatory bowel disease, it is critical to maintain suspicion in patients on prolonged immunosuppression to reduce complications.

INTRODUCTION
Kaposi sarcoma (KS) is an angioproliferative neoplasm that may present as 1 of 4 subtypes: classic, endemic, human immunodeficiency virus (HIV)-associated, and iatrogenic.1–6 Human herpesvirus-8 (HHV8) is the causative agent of each of these clinical subtypes, which may present with benign violaceous macules and subcutaneous nodules or involve the lymph nodes and viscera.2,3,5,6 Iatrogenic KS typically presents similarly to classic KS, with mucosal and cutaneous lesions, and has been associated with the use of cyclosporine, azathioprine, infliximab, methotrexate, and corticosteroids.1–5,7 Although iatrogenic KS more often develops in patients undergoing solid organ transplants, there have been rare reports of iatrogenic KS in patients with inflammatory bowel disease (IBD) on immunosuppressants.1–6,8–13 Gastrointestinal involvement is most often asymptomatic, although it may present with abdominal pain, diarrhea, and rectal bleeding, resembling an IBD flare.4,6 Screening endoscopy is not performed in patients without risk factors such as low CD4,100 cells/µL, men who have intercourse with men, and presence of cutaneous KS lesions.6 The current treatment for KS is doxorubicin, with paclitaxel as a second-line therapy.14 However, to our knowledge, chemotherapeutic agents have only been reported in 1 case of KS in a patient with IBD.15

Since the first case reported in 1966, there have been 26 published cases of iatrogenic KS in patients with IBD — 20 with ulcerative colitis (UC) and 6 with Crohn’s disease.15,16 These patients were on prolonged immunosuppressants because of severe refractory disease.5,16 We present the 21st case of an HIV-negative patient with UC who was diagnosed with disseminated iatrogenic KS and the second case in a patient with IBD that responded to pegylated liposomal doxorubicin.

CASE REPORT
A 24-year-old HIV-negative man with a history of UC and psoriasis presented with 12 episodes of watery, nonbloody diarrhea per day and a 20-pound weight loss over 1 month. The onset of diarrhea coincided with the start of amoxicillin, which he was taking for a
positive for enteropathic ACG Case Reports Journal / Volume 8 acgcasereports.com 2

DISCUSSION

This report discusses a case of iatrogenic KS in a patient with UC maintained on cyclosporine for 2 years. Previous reports of KS in patients with IBD described the characteristic cutaneous lesions after prolonged immunosuppressive therapy. In- testinal KS is exceedingly rare in HIV-negative individuals, with 5 reported cases of combined cutaneous and gastrointestinal involvement and 18 reported cases with gastrointestinal manifestations alone. Several therapies have been implicated in iatrogenic KS; however, few cases reported patients with IBD on long-term cyclosporine as in our patient. In the absence of skin lesions, KS may be difficult to identify in patients with IBD because its nonspecific symptomatology can be confounded by those of IBD itself.

Based on current literature, there is no association between the development of iatrogenic KS and the duration of IBD activity. Gastrointestinal involvement is usually asymptomatic and can occur in the absence of cutaneous lesions as demonstrated in our patient, which may obscure the diagnosis. Because KS most often affects the submucosa, superficial bowel biopsies rarely detect it and require submucosal biopsies with histologic evaluation. Previous cases of KS in patients with IBD suggest cessation of the immunosuppressive agent may be sufficient for disease resolution in the absence of systemic HHV-8 infection. Given the difficulty with preventing acute IBD flares on discontinuing these agents, patients in several cases needed partial or total colectomy for resolution of symptoms without recurrence.

Because of evidence of disseminated KS in our patient, rituximab and pegylated liposomal doxorubicin were initiated. Pegylated liposomal doxorubicin has been shown in several studies to be the preferred treatment of HIV-associated KS with gastrointestinal involvement, with similar efficacy in classic KS. However, there are limited cases that report the use of chemotherapeutic agents in patients with iatrogenic KS. We report the first known case of disseminated iatrogenic KS secondary to cyclosporine in a patient with IBD that has responded to treatment with pegylated liposomal doxorubicin with rituximab and did not require surgical intervention.

Figure 1. Colonoscopy images displaying hemorrhagic and ulcerated nodules in the (A) terminal ileum and (B) sigmoid colon.

Figure 2. (A and B) Hematoxylin and eosin stain that stained tissue sections of the colon biopsies demonstrates a vasoformative lesion composed of spindle cells with many small, poorly formed, slit-like vascular spaces involving the lamina propria and submucosa. Immunohistochemical stains demonstrate that this lesion is positive for endothelial markers CD31 and CD34 and for human herpesvirus-8.
DISCLOSURES

Author contributions: All authors contributed equally to this article. ML Borum is the article guarantor.

Previous presentation: This case was presented at the Crohn’s & Colitis Congress; February 7-9, 2019; Las Vegas, Nevada.

Financial disclosure: None to report.

Informed consent could not be obtained for this case report. All identifying information has been removed.

Received April 24, 2020; Accepted February 16, 2021

REFERENCES


Copyright: © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.